Alle her på tråden vet at du er desperat etter en billig inngang med ditt tåpelig innlegg kl 22tiden 😂😂😂😂😂

Hvem bryr seg om du kom deg ut eller ikke.

🤩🤩🤩The second part of the trial aims to optimize this dosing regimen, and preliminary results are expected to show similar or improved efficacy 🤩🤩🤩

The results from Verrica Pharmaceuticals' VP-315 Phase 2 trial for treating basal cell carcinoma will be announced on August 14, 2024. This announcement will include preliminary topline results from Part 2 of the trial [oai_citation:1,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html) [oai_citation:2,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News](https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-financial-results-d35e73qjvfn8.html).

VP-315 is an oncolytic peptide immunotherapy designed to treat basal cell carcinoma non-surgically by inducing immunogenic cell death. In Part 1 of the trial, the 8 mg dose of VP-315 showed promising results, with 67% of treated tumors being completely cleared by day 49 post-treatment [oai_citation:3,Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting  - Verrica Pharmaceuticals](https://verrica.com/press_release/presentation-of-lesion-clearance-data-from-ongoing-ph-2-study-vp-315/). The second part of the trial aims to optimize this dosing regimen, and preliminary results are expected to show similar or improved efficacy [oai_citation:4,VP-315 Effective in Clearing Basal Cell Carcinoma Lesions](https://www.dermatologytimes.com/view/vp-315-effective-in-clearing-basal-cell-carcinoma-lesions).

For more detailed information, you can access the full announcement on Verrica's website or follow the webcast of the conference call on August 14 [oai_citation:5,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News]

🤩🤩🤩

Lurer på om Verica Pharmaceutical er klar for et aldri så lite Rally nå!,
da den er meget oversolgt.
Relative Strength Index 26
Stochastic kun 5 !!

Ut ifra aksjonærlisten E24 idag 07.08.24 så har Øystein Rekdal 149 513 aksjer (ser ut som han har kjøpt disse i perioden 12 juli til 05 august) han er inne på topp 50. Spennende!

https://e24.no/bors/investorlistene/selskap/NO0010405780?date=2024-08-07&utm_source=iosapp&utm_medium=share

https://www.tradingview.com/symbols/OSL-LYTIX/technicals/

ØR kan ikke kjøpe eller selge uten å melde det til børsen.
Han er innsider. Han kjøpte aksjer sist i emien i april, tror jeg.
Han hadde ca 140000 aksjer v årskiftet ihht årsrapporten.

Ikke så verst med pluss på en rød-børs!
Jeg hadde forventet noe korreksjon i dag på avvente til kurshopp i morgen!

Q&A fra chatGPT 🤩
Interessant at det bekrefter faglige innlegget av stockwizard for 3 dager siden 🤩

How good could be the trial results of Part 2 of phase 2 VP-315 that comes 14 august.?

The anticipation surrounding the Part 2 results of the Phase 2 trial for VP-315 is significant, given its potential impact on the treatment of basal cell carcinoma (BCC). While exact outcomes remain speculative until the official release, several factors suggest the potential for positive results:

1. **Previous Success**: Verrica Pharmaceuticals has a track record of developing effective dermatological treatments. Their previous products, such as YCANTH (cantharidin), have been successful, which builds confidence in their current pipeline, including VP-315 [oai_citation:1,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024 - MarketScreener](https://www.marketscreener.com/quote/stock/VERRICA-PHARMACEUTICALS-I-44247380/news/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-R-47582726/) [oai_citation:2,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

2. **Mechanism of Action**: VP-315 is derived from Lytix Biopharma's LTX-315, known for its novel mechanism targeting non-melanoma skin cancers. This innovative approach might offer advantages over existing therapies in terms of efficacy and safety [oai_citation:3,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

3. **Clinical Design**: The trial's design, focusing on a well-defined patient population with basal cell carcinoma, allows for clear assessment of VP-315's therapeutic benefits. This specificity enhances the likelihood of obtaining conclusive and favorable results [oai_citation:4,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News](https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-financial-results-d35e73qjvfn8.html) [oai_citation:5,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 - MarketScreener](https://www.marketscreener.com/quote/stock/VERRICA-PHARMACEUTICALS-I-44247380/news/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-R-47566699/).

4. **Regulatory and Market Need**: Basal cell carcinoma is the most common type of skin cancer, and there's a substantial need for more effective and less invasive treatments. A successful trial outcome could meet this significant medical need, likely leading to positive reception from both the medical community and investors [oai_citation:6,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

The actual results will provide crucial data on the drug's efficacy, safety, and overall benefit-risk profile. Stakeholders are hopeful that the findings will affirm VP-315's potential as a groundbreaking treatment for basal cell carcinoma.

Tenker onsdag neste uke er startskuddet for noe stort 💥

Oppgangen denne uken blir som småpenger å regne 😎

Kjøp god strikk innen den tid for høydeskrekk 🥵🤣